Compare Citius Pharmaceuticals Inc (CTXR) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Kinross Gold Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Kinross Gold Corporation trades at $23.72 (market cap $27.62B). The key difference: Kinross Gold Corporation is far larger — about 2027.9× Citius Pharmaceuticals Inc's market cap, and Kinross Gold Corporation pays a 0.69% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Kinross Gold Corporation for 53 Days on average.
| CTXR | KGC | |
|---|---|---|
Market Cap | $13.62M | $27.62B |
Volume | 132,438 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $38.06 |
52-Week Low | $0.48 | $22.47 |
Typical Hold Time | 17 Days | 53 Days |
Enterprise Value | $3.79M | $25.70B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Kinross Gold (KGC) trades at $23.82, up 2.76% today, but faces a bearish technical signal despite strong fundamentals. The company reported robust earnings, beating estimates for three consecutive quarters, with 2025 revenue of $7.05 billion and net income of $2.39 billion. However, recent news highlights production guidance cuts and legal investigations, creating mixed sentiment. Valuation ratios appear attractive with a P/E of 8.87 and EV/EBITDA of 4.59, while analyst consensus remains bullish with a $38.80 price target.
The outlook for KGC is cautiously optimistic, driven by strong cash flow and gold price resilience, but near-term risks include operational setbacks and legal overhangs. Investment opportunity lies in its undervaluation and shareholder returns, yet investors must weigh production volatility and cost pressures against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
